Gainesville, FL–(business wire)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”) is dedicated to developing life-changing medicines through science and innovation for patients and families living with disease today. A clinical-stage biotechnology company. announced that its abstract was accepted for poster presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting, March 18-21, 2023 in Salt Lake City, Utah. did.
“I look forward to attending future SIMD Annual Meetings and cherishing the opportunity to further connect with all those dedicated to advancing scientific and clinical research to further elucidate the etiology and natural history of inherited metabolic disorders. Cyclo said Lise Kjems, M.D., Ph.D., Chief Medical Officer, Therapeutics.
“We believe in trapsol® Cyclo™ has the potential to be a safe and effective treatment for NPC, and continues to be bolstered by advances in TransportNPC, an ongoing Phase 3 clinical trial. We look forward to further engaging with the community at this important conference to raise awareness of our clinical research and important unmet needs,” he added Dr. Kjems.
The details of the poster presentation are as follows.
|
Poster number: |
84 |
|
|
Title: |
TransportNPC: Trappsol Phase 3 Global Trial® Cyclo™ administered intravenously to patients with Niemann-Pick disease type C1 (NPC1) |
|
|
Presenter: |
Joseph Mejia, MD, Senior Medical Science Liaison for Cyclo Therapeutics US & LATAM |
|
|
Date and time: |
Sunday, March 19, 7pm-10pm |
For more information on the event, please visit the conference website here.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines for patients living with disease and their families through science and innovation.The company’s trapsol® Cyclo™ has orphan drug designation in the US and Europe and is the subject of four formal clinical trials in Niemann-Pick disease type C, a rare and fatal genetic disease (www. ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). We are conducting a Phase 2b clinical trial with Trapsol.® Intravenous administration of Cyclo™ in early Alzheimer’s disease (NCT05607615) based on encouraging data from the Alzheimer’s Disease Extended Access Program (NCT03624842).Additional effect of trapsol active ingredient® Cyclo™ is under development. For more information, please visit our website www.cyclotherapeutics.com.
safe harbor declaration
This press release contains “forward-looking statements” regarding our current expectations regarding future results, performance, prospects and opportunities. Statements that are not historical facts, such as “expect,” “believe,” “expect,” or similar expressions are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from those expressed or implied by these statements. Factors that may affect the Company’s future results include the Company’s ability to obtain additional capital to grow its business as planned, and its success in achieving regulatory approval of its clinical protocols. , enrolling sufficient numbers of patients in clinical trials, and unforeseen difficulties in demonstrating the company’s efficacy. biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with manufacturing pharmaceutical grade and food products; These and other risk factors are described from time to time in the Company’s filings with the Securities and Exchange Commission, including but not limited to the Company’s reports on Forms 10-K and 10-Q. We undertake no obligation to update or revise any forward-looking statements as a result of new information or future events, except as required by law.
